Difference between revisions of "Thrombocytopenia in liver disease"
Jump to navigation
Jump to search
(Created page with "== Thrombocytopenia in liver disease with planned procedure == <big>Avatrombopag (Doptelet)</big> {| class="wikitable" |- ! Study !! Evidence !! Comparator !! Efficacy |- |...") |
|||
| Line 14: | Line 14: | ||
'''Avatrombopag''' | '''Avatrombopag''' | ||
| − | * High dose 60 mg/d PO on days 1 to 5 (Patients with platelet count < 40 x 10<sup>9</sup>/L) | + | * High dose 60 mg/d PO on days 1 to 5 (Patients with platelet count <40 x 10<sup>9</sup>/L) |
| − | * Low dose 40 mg/d PO on days 1 to 5 (Patients with platelet count 40 x 10<sup>9</sup>/L - < 50 x 10<sup>9</sup>/L) | + | * Low dose 40 mg/d PO on days 1 to 5 (Patients with platelet count 40 x 10<sup>9</sup>/L - <50 x 10<sup>9</sup>/L) |
Procedure days were days 10 to 13. | Procedure days were days 10 to 13. | ||
Revision as of 16:38, 22 May 2018
Thrombocytopenia in liver disease with planned procedure
Avatrombopag (Doptelet)
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| ADAPT-1 | Phase III | Placebo | Superior RR |
| ADAPT-2 | Phase III | Placebo | Superior RR |
Avatrombopag
- High dose 60 mg/d PO on days 1 to 5 (Patients with platelet count <40 x 109/L)
- Low dose 40 mg/d PO on days 1 to 5 (Patients with platelet count 40 x 109/L - <50 x 109/L)
Procedure days were days 10 to 13.